A

AnaptysBio
D

ANAB

22.280
USD
1.12
(5.29%)
Market Closed
Volume
9,510
EPS
-6
Div Yield
-
P/E
-4
Market Cap
677,951,035
OverviewSignalsIdeasNews
Related Instruments
    A
    ACAD
    -0.240
    (-1.41%)
    16.790 USD
    ALNY
    ALNY
    -22.650
    (-8.77%)
    235.480 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    ESPR
    0.03000
    (1.43%)
    2.13000 USD
    N
    NBIX
    -5.465
    (-4.45%)
    117.410 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    V
    VKTX
    -3.960
    (-7.39%)
    49.620 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    More
News

Title: AnaptysBio

Sector: Healthcare
Industry: Biotechnology
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA)and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).